Bluebird’s star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech startups – Endpoints News
Endpoints News |
Bluebird's star gene therapy patient still doing well after 15 months-plus; Takeda, Arix partner on biotech startups
Endpoints News Patient 1204 in bluebird's program for LentiGlobin gene therapy program has had more than 15 months of followup, and his physicians say that the teenager has been free of the painful symptoms of sickle cell disease, able to lead a normal life and stop … |
